ClinicalTrials.gg
CompletedNCT01785095Updated Feb 9, 2017Results posted

Immunogenicity of Repeated Follicle Stimulating Hormone (FSH) Stimulation Cycles

A Phase 3 interventional study of FSH (Follicle Stimulating Hormone) in Oocyte Donation, sponsored by IBSA Institut Biochimique SA. Completed at 1 site in Spain. Open to female participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-02-09.

Sponsored by IBSA Institut Biochimique SA · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
41
Allocation
Not applicable
Ages
18 Years to 35 Years
Sex
Female
01

Study summary

The purpose of the study is to evaluate immunogenic potential of FSH-IBSA in healthy volunteers undergoing controlled ovarian hyperstimulation (COH) in an oocyte donation program.

02

Conditions studied

  • Oocyte Donation
03

In context

Lead sponsor

IBSA Institut Biochimique SA is the lead sponsor of 33 studies on the registry; 1 is open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy female volunteers undergoing controlled ovarian hyperstimulation for oocyte donation with the following characteristics:
  • Able and willing to sign the Subject Consent Form and adhere to the study visit schedule;
  • >=18 and \<35 years old;
  • Regular menstrual cycle (26 - 35 days);
  • between 18 and 30 kg/m2;
  • First gonadotrophin treatment (i.e. naïve Subjects with regard to exposure to human derived or recombinant gonadotrophins);
  • basal FSH \<10 IU/L and E2 \<80 pg/ml (\~290 pmol/l);
  • Normal TSH levels;
  • Willing to perform at least two consecutive oocyte retrieval cycles (with a wash out period of two months).

Exclusion criteria

Exclusion Criteria:

  • Age \<18 and >=35 years;
  • PCOS;
  • Endometriosis;
  • Subjects with evidences of or rheumatic diseases;
  • to the active substance or to any of the (lactose);
  • Abnormal bleeding of undetermined origin;
  • Subject found to be positive to anti-TSH antibodies (i.e. suffering from thyroidal diseases);
  • Uncontrolled adrenal dysfunction;
  • Neoplasia;
  • Severe impairment of renal and/or hepatic function;
  • Use of concomitant medications that might interfere with study evaluations (e.g. , non-study hormonal medications, therapeutics proteins like insulin, growth hormone...).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    FSH

    FSH (Follicle stimulation hormone, 75 IU/vial) will be administered to women according to their need and response assessed by the Investigator.

    Drug: FSH (Follicle Stimulating Hormone)

06

What researchers measure

Primary outcomes

  1. Number of Patients Producing Anti-FSH Antibodies.

    The immunogenicity potential of FSH in healthy volunteer will be assessed by analysing serum samples collected at different timepoints during two treatment cycle for oocytes donation: cycle 1, serum samples will be collected before treatment start (baseline), after 7-13 days and after 28 days of treatment; Cycle 2: serum samples will be collected before starting the second cycle (baseline 2), after 7-13 days and after 28 days of treatment. Cycle 1 and cycle 2 will be separated by a wash-out period of two months.

    Time frame: 4 months.

Secondary outcomes

  1. Number of Oocytes Retrieved

    the number of oocytes retrieved in the first cycle and in the second cycle are compared.

    Time frame: after 2 weeks of treatment

  2. Total Dose of FSH Units Used.

    Time frame: after 2 weeks of treatment

07

Results

Posted Mar 27, 2015

Participant flow

Participant flow — Overall Study
MilestoneFollicle Stimulation Hormone
Started27
Completed24
Not completed3

Outcome measures

PrimaryNumber of Patients Producing Anti-FSH Antibodies.

The immunogenicity potential of FSH in healthy volunteer will be assessed by analysing serum samples collected at different timepoints during two treatment cycle for oocytes donation: cycle 1, serum samples will be collected before treatment start (baseline), after 7-13 days and after 28 days of treatment; Cycle 2: serum samples will be collected before starting the second cycle (baseline 2), after 7-13 days and after 28 days of treatment. Cycle 1 and cycle 2 will be separated by a wash-out period of two months.

Time frame:
4 months.
Reported as:
Number · participants
Number of Patients Producing Anti-FSH Antibodies.
participantsFollicle Stimulationg Hormone
Number of Patients Producing Anti-FSH Antibodies.0
SecondaryNumber of Oocytes Retrieved

the number of oocytes retrieved in the first cycle and in the second cycle are compared.

Time frame:
after 2 weeks of treatment
Reported as:
Mean · oocytes
Number of Oocytes Retrieved
oocytesFirst CycleSecond Cycle
Number of Oocytes Retrieved13.4 ± 7.715.7 ± 7.8
SecondaryTotal Dose of FSH Units Used.
Time frame:
after 2 weeks of treatment
Reported as:
Mean · IU
Total Dose of FSH Units Used.
IUFirst CycleSecond Cycle
Total Dose of FSH Units Used.1911.1 ± 604.81984.4 ± 622.4

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Follicle Stimulating Hormone—1/27 (3.7%)7/27 (25.9%)
Most frequent serious events
Most frequent serious events
EventFollicle Stimulating Hormone
HaemorrhageInjury, poisoning and procedural complications1/27
Most frequent other events
Most frequent other events
EventFollicle Stimulating Hormone
HeadhacheNervous system disorders3/27
abdominal painGastrointestinal disorders1/27
PirexiaGeneral disorders1/27
bacterial vaginosisInfections and infestations1/27
candida infectionInfections and infestations1/27
lymp injuryInjury, poisoning and procedural complications1/27
Back painMusculoskeletal and connective tissue disorders1/27
Muscle spasmMusculoskeletal and connective tissue disorders1/27
DizzinessNervous system disorders1/27

Baseline characteristics

All the subjects that started the stimulation.

Age, Continuous
Age, Continuous(years)Follicle Stimulating Hormone
Mean25.7 ± 5.4
Gender
Gender(Participants)Follicle Stimulating Hormone
Female27
Male0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Follicle Stimulating Hormone
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White27
More than one race0
Unknown or Not Reported0
BMI (kg/m2)
BMI (kg/m2)(kg/m2)Follicle Stimulating Hormone
Mean21.7 ± 2.0
08

Study locations

1 site
  • Dep.Obstet-Gynec.-Reproduction,Institut Universitari Dexeus
    Barcelona, 8028, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2013, a primary completion of Jul 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2015, 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2013
First posted
Feb 7, 2013
Start
Mar 2013
Primary completionActual
Jul 2014
CompletionActual
Nov 2014
Results first posted
Mar 27, 2015
Last update
Feb 9, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01785095
Responsible party
Sponsor
First posted
Feb 7, 2013
Start date
Mar 2013
Primary completion
Jul 2014
Completion
Nov 2014
Results posted
Mar 27, 2015
Last update
Feb 9, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Follicle Stimulating Hormone

Start the discussion